Mirabegron

CAS : 223673-61-8

Ref. 3D-FM26011

Informations sur le produit

• Nom: Mirabegron
• Synonymes: 2-Amino-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-thiazoleacetamide(2R)-2-(2-Aminothiazol-4-yl)-4'-[2-[(2-hydrox y-2-phenylethyl)amino]ethyl]acetic acid anilideYM 178, (R)-Mirabegron, 2-(2-Amino-1,3-thiazol-4-yl)-N-[4-[2-[((2R)-2-hydroxy-2-phenylethyl)amino]ethyl]phenyl]acetamide, 2-(2-amino-1,3-thiazol-4-yl)-N-(4-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}phenyl)acetamide, 2-Amino-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-thiazoleacetamide, 4-Thiazoleacetamide, 2-amino-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, Betanis, Betmiga, Mira veron, Myrbetriq, N-(4-(2-(2-hydroxy-2-phenylethylamino)ethyl)phenyl)-2-(2-aminothiazol-4-yl)acetamide, Ym 178
• CAS: 223673-61-8

Description

Mirabegron is a drug that is used for the treatment of urinary incontinence and overactive bladder. It is a selective beta 3 adrenergic receptor agonist that has been shown to increase detrusor muscle contractility, thereby improving the storage capacity of the bladder. Mirabegron also decreases post-voiding residual volume and increases total voided volume. Mirabegron acts by binding to its receptor in adipose tissue, which leads to increased lipolysis and reduced appetite. The effect on lipolysis may be due to mirabegron's ability to inhibit DPP-IV activity.

The following are high-quality product descriptions for eCommerce:

Rifapentine is an anti-tuberculosis drug that belongs to the class of rifamycins. It is the most active of the rifamycins for the treatment of tuberculosis. Rifapentine inhibits bacterial growth by binding to DNA-dependent RNA polymer

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 396.51 g/mol
• Formule: C₂₁H₂₄N₄O₂S
• Degré de pureté: Min. 95 Area-%
• Couleur/Forme: White Off-White Powder